Loading company…
Obatala Sciences develops human-derived biomaterials for preclinical drug research.
Founded in 2017 and based in New Orleans, Obatala Sciences develops biomaterials including hydrogels, stem cells, and Fat-on-a-Chip models for preclinical drug development. Its ObaGel® and ObaCell® technologies support research by pharmaceutical companies and academic institutions. In October 2022, it raised USD 3.000 mn in Series A funding co-led by être Venture Capital and Ochsner Clinic Foundation Retirement Plan.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in